Vimarsana
Biggest News Aggregation in the World

Rev Cardiol News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rev Cardiol. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rev Cardiol Today - Breaking & Trending Today

Leducq-funded transatlantic network set to pioneer new diagnosis and treatment of heart disease - Vimarsana News

Leducq-funded transatlantic network set to pioneer new diagnosis and treatment of heart disease

Professor David Paterson, in collaboration with the UCLA’s Professor Kalyanam Shivkumar, has been awarded a prestigious Leducq International Network of Excellence Program Award of $8 million (£6.3M) to set up a major new transatlantic network linking world leading researchers from the USA and Europe to develop ‘Bioelectronics for neurocardiology diagnosis and therapeutics’.

Source: ox.ac.uk
Machine learning-based marker for coronary artery disease: derivation and validation in two longitudinal cohorts - Vimarsana News

Machine learning-based marker for coronary artery disease: derivation and validation in two longitudinal cohorts

Electronic health record-based machine learning was used to generate an in-silico marker for coronary artery disease that can non-invasively quantify atherosclerosis and risk of death on a continuous spectrum, and identify underdiagnosed individuals.

AstraZeneca: New data show FARXIGA significantly lowers the risk of cardiovascular death in patients with heart failure - Vimarsana News

AstraZeneca: New data show FARXIGA significantly lowers the risk of cardiovascular death in patients with heart failure

Pre-specified pooled analysis from Phase III trials demonstrated reduction in CV death by 14% and reduction in death from any cause by 10% in patients with heart failure irrespective of ejection fraction

FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial - Press Release - Vimarsana News

FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial - Press Release

Results presented at European Society of Cardiology Congress 2022, and published in New England Journal of Medicine Data extend the clinically meaning

What is Immunoengineering? - Vimarsana News

What is Immunoengineering?

Immunoengineering refers to a new discipline that applies on create engineering tools and principles to both investigate and change the immune system